| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(2 years from now) | |
| US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(5 years from now) | |
| US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(11 years from now) | |
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(12 years from now) | |
Isturisa is owned by Recordati Rare.
Isturisa contains Osilodrostat Phosphate.
Isturisa has a total of 6 drug patents out of which 0 drug patents have expired.
Isturisa was authorised for market use on 06 March, 2020.
Isturisa is available in tablet;oral dosage forms.
Isturisa can be used as cushing's disease.
Drug patent challenges can be filed against Isturisa from 2024-03-06.
The generics of Isturisa are possible to be released after 12 October, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 6, 2025 |
| Orphan Drug Exclusivity (ODE) | Mar 6, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 2024-03-06
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL
ISTURISA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic